Exploring Growth and Innovation in the Plasma Fractionation Industry

In 2023, the plasma fractionation market was valued at approximately $32.75 billion. By 2034, this market is expected to surge to $72.86 billion, reflecting an impressive compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. This rapid growth is fueled by the increasing demand for plasma-based therapies, which continue to drive advancements and opportunities within the industry.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5320

Recent Developments in the Plasma Fractionation Market

• In September 2024, Epsilogen, a leading biotechnology company based in London, secured $16.4 million in funding to advance the development of its immunoglobulin E (IgE) antibodies for cancer treatment. Key investors included British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, and ALSA Ventures.
• In June 2024, Biotest, a global supplier of plasma protein products and biotherapeutic drugs under the ownership of Grifols, received FDA approval for Yimmugo. This innovative treatment is designed for patients aged two years and older with primary humoral immunodeficiency (PI).
• In July 2024, the Independent Health and Aged Care Pricing Authority introduced Activity-Based Funding (ABF) for home-delivered subcutaneous immunoglobulin (SCIg) infusion therapy. This program enables patients to self-administer therapy at home, eliminating the need for healthcare provider assistance.

Regional Insights

North America: Leading the Plasma Fractionation Market with Strong R&D Investments

North America held the largest share of the global plasma fractionation market in 2023, with the United States as the world’s top plasma supplier. The U.S. operates a paid donor system, unlike many other countries that rely on unpaid, volunteer donors, leading to significantly higher plasma collection rates. Canadian Blood Services leverages raw plasma for producing drugs like plasma proteins and related products. In the U.S., three major plasma product companies—CSL Plasma, Grifols, and BioLife—collect over 75% of the total plasma used for fractionation. Notably, the number of plasma donation centers in the U.S. has increased by 54% over the past four years. With the growing demand for plasma, estimated at 6,500 units daily, maintaining a consistent donation rate remains crucial for meeting global needs.

Europe: Poised for Rapid Growth and Strategic Advancements

Europe is projected to experience the fastest growth in the plasma fractionation market between 2024 and 2034. This growth is driven by the European Union’s focus on achieving open strategic autonomy and enhancing competitiveness in the plasma sector. Collaborative efforts by EU institutions, governments, and businesses aim to address vulnerabilities and implement policies that ensure a resilient supply of plasma and plasma-derived medicinal products. These measures are expected to strengthen both regional and national strategies, fostering recognition and sustainability in Europe’s plasma fractionation industry.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fractionation-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5320

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare